Molecular Partners AG (NASDAQ:MOLN – Get Rating) – Equities researchers at SVB Leerink raised their FY2022 EPS estimates for shares of Molecular Partners in a note issued to investors on Wednesday, November 23rd. SVB Leerink analyst D. Graybosch now forecasts that the company will earn $4.01 per share for the year, up from their prior forecast of $3.79. SVB Leerink currently has a "Market Perform" rating and a $8.00 target price on the stock. The consensus estimate for Molecular Partners' current full-year earnings is $3.52 per share.

Molecular Partners (NASDAQ:MOLN – Get Rating) last posted its earnings results on Thursday, October 27th. The company reported ($0.42) earnings per share (EPS) for the quarter. The business had revenue of $2.45 million for the quarter.

Molecular Partners Stock Up 4.7 %

NASDAQ MOLN opened at $6.69 on Thursday. Molecular Partners has a 52 week low of $5.50 and a 52 week high of $32.04. The company has a 50-day moving average price of $6.38 and a 200-day moving average price of $6.57.

Institutional Trading of Molecular Partners

Several institutional investors and hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. increased its stake in shares of Molecular Partners by 94.2% during the first quarter. Federated Hermes Inc. now owns 457,037 shares of the company's stock valued at $9,264,000 after buying an additional 221,743 shares during the period. Tang Capital Management LLC acquired a new stake in Molecular Partners in the third quarter worth about $105,000. Finally, AlphaCentric Advisors LLC acquired a new stake in Molecular Partners in the third quarter worth about $218,000. 2.70% of the stock is currently owned by institutional investors.

About Molecular Partners

(Get Rating)

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.

Read More

• Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
• Institutional Support for Analog Devices Remains High
• Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
• Three CBD Stocks to Dominate a Budding Industry
• Is the 60/40 Portfolio Mix Still in Vogue?
• Microsoft Shares: Is it Time to Back Up the Truck?

Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.